In a recently published randomized double blind clinical trial with the multi-targeted tyrosine kinase inhibitor midostaurin, an improvement of overall survival of FLT3-mutated AML patients compared to placebo was demonstrated [12]. Here, FLT3 is linked to acute myeloid leukemia.